Alltracel Pharmaceuticals plc
Alltracel's Nanopeutics subsidiary signs new Professional Wound Care
technology development agreement with ConvaTec
November 12, 2007: London, UK & Dublin, Ireland
Alltracel Pharmaceuticals Plc., ("Alltracel" or "the Company"), (AIM:AP.L), the
healthcare innovation group focused on oral care, wound care, cardiovascular
health and dermal health markets, today announces that its Nanopeutics
subsidiary has signed a collaborative technology development agreement with
ConvaTec, a world-leading manufacturer of ostomy and wound care products with a
25-year heritage of caring for patients.
ConvaTec has been working with Alltracel since November 2006, when the initial
primary concept development agreement was announced with a professional wound
care partner. As per the original agreement, today's new technology agreement
will be funded by ConvaTec and its successful conclusion may lead to an
exclusive royalty bearing license and supply agreement between both companies.
As part of the development work under the previous agreement, Alltracel's
healthcare services division (Alltracel Healthcare Services) was also contracted
by ConvaTec to perform laboratory testing and analysis work. The extension of
the collaboration between Alltracel and ConvaTec will also include similar
laboratory testing and analysis work by Alltracel Healthcare Services.
Alltracel's Chief Executive Officer, Tony Richardson commented:
"We are very pleased to announce our continuing collaboration with ConvaTec. Our
new agreement in the area of professional wound care product development further
supports the strength of Alltracel's development work carried out to date for
ConvaTec and we look forward to progressing the commercialisation of our
professional wound care products in 2008 and beyond. The professional wound
care area is an important market for us and we are happy to be collaborating
with a partner of ConvaTec's caliber and heritage. Alltracel's Nanospider(TM)
technology affords many possibilities in this sector and seeks to improve
product performance and assist in the treatment of many patients."
Michael J Lydon PhD, Vice President Global R&D in ConvaTec commented:
"ConvaTec acknowledges the significant commercial opportunities that
nanotechnology presents in the field of professional wound care. This agreement
recognizes our continuing commitment to develop this technology to enhance
products and offer improved wound care solutions for our patients."
ENDS
For Further Information Contact:
Dublin: Karen Muldowney Alltracel: +353 1 235 2162 press@alltracel.com
London: Deborah Scott Financial Dynamics: +44 207 831 3113
Notes to Editors:
Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.
Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:
Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovative technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, Dermal Health and Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Synpart Limited
(www.synpartlimited.com) with offices in the UK and Germany is the leading
contract supply and manufacturing partner for the European private label
inter-dental market and also partners with a number of leading oral care brands
internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of Nanospider(TM)technology for the global
healthcare market.
- Alltracel Healthcare Services provides Scientific Research, Clinical
Trial & Development Services for Healthcare companies seeking a step up in speed
of Healthcare Innovation.
Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas such as Wound Care, Oral Care, Cardiovascular
Health and Dermal Health.
ConvaTec Information
ConvaTec, a world-leading manufacturer of ostomy and wound care products with a
heritage of caring about patients, is a Bristol-Myers Squibb Company (NYSE: BMY ).
Bristol-Myers Squibb is a global pharmaceutical and related health care
products company.
ConvaTec's Wound Therapeutics(TM)franchise pursues a comprehensive approach that
grounds our advanced science in the everyday realities of wound and skin care.
The company's Chronic Care franchise develops innovative products and
product-related services to help people with an ostomy get back to their
everyday activities and live their lives to the fullest. For more information
please visit www.convatec.com.
Wound Therapeutics(TM)is a trademark of ConvaTec, a Division of E.R. Squibb &
Sons, LLC
m-doc(TM)& Phytopeutics(TM)are trademarks of Alltracel Pharmaceuticals plc.
Nanospider(TM)and Nanopeutics(TM)are trademarks controlled by Nanopeutics s.r.o.
This information is provided by RNS
The company news service from the London Stock Exchange
Alltracel Pharmaceuticals Plc announces Nanopeutics Agreement
| Source: Alltracel Pharmaceuticals Plc
DUBLIN, IRELAND--(Marketwire - November 12, 2007) -